Peter Blume-Jensen - 14 Nov 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: President and CEO, Director
Signature: /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Issuer symbol: ACRV
Transactions as of: 14 Nov 2022
Net transactions value: $0
Form type: 4
Filing time: 16 Nov 2022, 18:05:47 UTC
Previous filing: 09 Nov 2022
Next filing: 01 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRV	Common Stock	Award	$0	+934,731	+107%	$0.000000	1,806,588	14 Nov 2022	Direct	F1
transaction	ACRV	Common Stock	Award	$0	+503,419	+28%	$0.000000	2,310,007	14 Nov 2022	Direct	F2
transaction	ACRV	Common Stock	Award	$0	+60,090	+2.6%	$0.000000	2,370,097	14 Nov 2022	Direct	F3
transaction	ACRV	Common Stock	Award	$0	+26,707	+9.1%	$0.000000	320,705	14 Nov 2022	See footnote	F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRV	Stock Option (Right to Buy)	Award	$0	+180,269		$0.000000	180,269	14 Nov 2022	Common Stock	180,269	$12.50	Direct	F6
transaction	ACRV	Stock Option (Right to Buy)	Award	$0	+80,120		$0.000000	80,120	14 Nov 2022	Common Stock	80,120	$12.50	See footnote	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. This RSU grant to the Reporting Person constitutes a number of shares equal to 3.5% of the total outstanding shares of the Issuer as of the pricing of the Issuer's initial public offering, on a fully diluted basis after giving effect to the offering.
F2	These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. This RSU grant to the Reporting Person constitutes a number of shares equal to 1.885% of the total outstanding shares of the Issuer as of the pricing of the Issuer's initial public offering, on a fully diluted basis after giving effect to the offering, meant to cover estimated tax liability at the time of settlement of the RSU award referred to in footnote 1.
F3	These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F4	These shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F5	These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F6	Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.